Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
Joakim BergmanAnders SvenningssonPer LivTommy BergenheimJoachim BurmanPublished in: Fluids and barriers of the CNS (2020)
A substantial heterogeneity in the protein levels of samples obtained from different CNS compartments was seen. Therefore, data obtained from analysis of lumbar CSF should be interpreted with caution when making conclusions about pathophysiological processes in brain tissue.
Keyphrases
- clinical trial
- multiple sclerosis
- blood brain barrier
- protein protein
- mass spectrometry
- white matter
- amino acid
- minimally invasive
- resting state
- diffuse large b cell lymphoma
- ms ms
- single cell
- electronic health record
- open label
- big data
- study protocol
- functional connectivity
- double blind
- phase ii
- brain injury
- subarachnoid hemorrhage
- chronic lymphocytic leukemia